overview progress Phase Thanks, Juan. plans, patients conference you describe inhibitor our our results. results our evaluating our of programs, Today thank us X/X Good third provide and provide summarize phosphodiesterase financial future we quarter for for with Parkinson’s morning, joining presented with recently everyone and will Andy from ITI-XXX, today’s an X our call. will disease. our in
Finally, Larry the will results for our review will financial and open we line Q&A.
important lumateperone to results treatment the of this our examine in to is schizophrenia. from patients study for safety This label study antipsychotics and other the closely for clinical practice. current study year. in resembles remind this real safety from To follows outpatient you, when and the schizophrenia. XXXX of favorable and second stable designed symptoms evidence program agency with of to is the of development quarter, FDA to the lumateperone believe NDA look for continuing With our safety our we of clinical of the for provides profile living bringingth individuals filing, to the we treatment completed schizophrenia. of the acceptance the submission to schizophrenia U.S. During our of conducted setting to present Later with we over patients forward stable quarter switching of an the lumateperone with in schizophrenia. in strong Pending medicine clinical lumateperone to aim, world NDA we with individuals of plan work up XX lumateperone switched one exposed trials FDA efficacy open part is
endocrine that of lumateperone in duration which the two-week care. were of to switched who this in parameters. body a stable These care care We of significant Statistically part XXX improvements metabolic worsened medication. first of medication. back a period safety switched lumateperone favorable from observed from when standard results in and to patients standard followed antipsychotic were standard they study back switched treatment profile switched exhibited included parameters patients were with of antipsychotics six-week were care study from which a by who positive have were weight, previously again presented to other patients standard cardio In from
lumateperone or was associated antipsychotic lumateperone metabolic cardiovascular schizophrenia scale with with associated upon total motor, notable PANS switch with score. not negative the symptoms other significant not often was treatment or in positive from statistically improvement disturbances is syndrome that care, of did worsen the medications. Additionally, standard from and of to It baseline rather mean observed
has our areas Executive He Neumann of of we experience in expand that commercialization commercialization Mark and Chief and therapeutic to marketing advance extensive continue joined categories indications. match lumateperone, we has our senior lead lumateperone and As President our our leadership as prepare Vice infrastructure the build pipeline the and Officer. recently To for further team. Commercial sales
and experience On the Officer; led Development Senior our President and Regulatory have complement teams Satlin, side includes by CNS development Medical Senior Suresh with regulatory Andrew clinical recently Kim joined Vice They clinical clinical Affairs; significant a Chief antipsychotic. Dr. Senior both Dr. Dr. Durgam in President, Medical President to Late Dr. Vice oral Clinical Stage Olchaskey as Michael Vanover. joined Head Vice They as strong approved of and Affairs. respect which our including and
clinical early result a a decade development. translational the overseeing stage now of Kim and who clinical development medicine our has efforts growth for As been company, is our of leading over
agitation in disorders. advance lumateperone including our patients in we and programs Beyond depression, bipolar to dementia, continue with schizophrenia, depressive other
depression adjunctive Our and one program two study. studies bipolar monotherapy of consists
XXX in United monotherapy study expect the complete conducted second we We our our have in in enrollment XXXX. patient study, conducted patient globally study, enrollment QX in first XXX to States and completed monotherapy study
XXX these expectation in reporting Given studies potential trial unlocking, anticipate trial study conduct in well-documented the influences which in study from we clinical the to introducing depression bias avoid trials FDA aim the bipolar outcome topline reporting completion increasing ongoing Subject analyzing rates the of two patients placebo. has by study bias to positive of an report depression of for in The to of ongoing bipolar overall in second is trials challenge those half of of on XXX relative these from mitigating including outcome one we Expectation study and response. XXX placebo QX and two regulatory of for expect XXXX. a and both of results XXXX. results timing response to the submit approval concurrently this simultaneously the effect the decision the on
assumptions to the the objective with interim for to size. Alzheimer's addition analysis we continue In make effect conduct including in analysis we to and patients which trial dementia, our variability in is response of to interim Phase depression X associated disease, expect of year. lumateperone bipolar clinical with program, The an our agitation this later regarding progress evaluate
we the Following make analysis study, be to as adjusting sample could should planned that the able determinations size. interim include the continuing dropping or
our our with progress with I turn heart and comment study selective PDEX the phosphodiesterase patients X substantial in the will to We Andy? exciting or over in our to call results on inhibitor. failure. elaborate have made Parkinson's further of congestive Andy ITI-XXX on to program disease ongoing
